🇫🇷 TME Pharma N.V.
ALTME.PAFundamentals
Gross Margin
-
Op. Margin
-
Net Margin
-
ROIC
-
Rev Growth
11.8%
Valuation
Price
0.12 EUR
Day
+0.00%
52-Week Range
0.05 - 0.17
Market Cap
12M EUR
Fwd P/E
-
EV/EBITDA
-
Div Yield
-
Annual income statement #
TME Pharma N.V. annual revenue, operating income and net income in EUR, 2014 to 2024. Revenue was 19,000 in 2024.
| Year | Revenue (EUR) | Operating income | Net income | Net margin |
|---|---|---|---|---|
| 2024 | 19,000 | -5.3m | -5.7m | |
| 2023 | 17,000 | -5.6m | -6.7m | |
| 2021 | 33,000 | -13.3m | -14.5m | |
| 2020 | 35 | -5.8m | -10.4m | |
| 2019 | 154 | -3.9m | -861,000 | |
| 2017 | 234,000 | -4.7m | -5.4m | |
| 2016 | 83,000 | -8.6m | -10.7m | |
| 2015 | 43,000 | -14.8m | -16.1m | |
| 2014 | 25,000 | -13.2m | -13.8m |
Financial Data #
Segment Breakdown #
Peers #
ACTI.ST ALNFL.PA BIOVIC-B.ST POXEL.PA SIMRIS-B.ST NXTCL.ST NICA.ST XINT.ST CYAD.BR AELIS.PA ·
Compare in Screener
Dividends
Bubble
Events #
| Date | Type | Details | Price | Amount |
|---|